NCCN awards grants for metastatic prostate cancer quality initiatives
- NCCN ORP awards grants for four mPCA quality improvement projects
- Funding and oversight provided by Pfizer Global Medical Grants
- Projects target biomarker testing, polypharmacy reduction, and care standardization
- Selected researchers include experts from UT Southwestern, Georgetown, Northwestern, and Moffitt
- Initiatives aim to close treatment gaps and increase clinical trial access
*this image is generated using AI for illustrative purposes only.
The National Comprehensive Cancer Network (NCCN) announced funding awards for quality improvement research projects focused on metastatic prostate cancer (mPCA). The NCCN Oncology Research Program (ORP) selected four initiatives to advance healthcare quality and provider performance, with funding and oversight provided by Pfizer Global Medical Grants.
The awards address critical gaps in mPCA care, including healthcare access disparities, variability in care delivery, limited support systems, and inequitable access to clinical trials. Many patients do not receive the full range of life-prolonging therapies for which they are eligible due to geographic, insurance, and infrastructure barriers.
Selected Projects
The funded projects aim to standardize testing, enhance clinical decision-making, and increase clinical trial participation. Proposals were reviewed by a Scientific Review Committee comprising peer experts from NCCN Member Institutions. All projects are set to be completed within two years.
| Researcher | Institution | Project Focus |
|---|---|---|
| Changchuan Jiang, MD | UT Southwestern Simmons Comprehensive Cancer Center | Closing the biomarker action loop in a U.S. safety-net cancer program |
| Paul Leger, MD | Georgetown University | Multilevel interventions to improve care in the Medstar Health Network |
| Michael Liu, MD, MPH | Northwestern University | Reducing polypharmacy burden to improve treatment tolerability |
| Kosj Yamoah, MD, PhD | Moffitt Cancer Center | Molecular readiness pathway for germline, somatic, and ctDNA testing |
Strategic Impact
Crystal S. Denlinger, MD, CEO of NCCN, emphasized the need for collaborative efforts to ensure access to evidence-based, guideline-concordant care. She noted that optimal care results in better outcomes for patients living with cancer. The organization stated its commitment to developing projects that are impactful, scalable, and sustainable for long-term benefit.
The NCCN ORP supports preclinical, translational, and clinical research at member institutions. It also maintains shared resources, an informed consent database, and guidelines for biorepositories to foster collaboration in cancer research.
Historical Stock Returns for Pfizer
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.86% | -12.57% | -16.76% | -15.47% | -21.02% | 0.0% |
How might the success of these NCCN-funded initiatives influence Pfizer's future strategic investments in prostate cancer care infrastructure?
What regulatory or reimbursement hurdles could prevent the scaling of these standardized testing and care protocols beyond the initial two-year project timeline?
Will the data generated from closing biomarker action loops in safety-net programs lead to revised NCCN clinical practice guidelines for metastatic prostate cancer?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
